FEMY vs SSKN vs MMSI vs CODA vs BDX

For growth investors, Femasys Inc.

(FEMY) is the stronger pick with 40. 8% revenue growth year-over-year, versus 0. 6% for STRATA Skin Sciences, Inc. (SSKN). Becton, Dickinson and Company (BDX) offers the better valuation at 25. 6x trailing P/E (11. 9x forward), making it the more compelling value choice. Analysts rate Merit Medical Systems, Inc. (MMSI) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Becton, Dickinson and Company (BDX) is the cheapest at 25.

6x versus Coda Octopus Group, Inc. at 32. 7x. On forward P/E, Becton, Dickinson and Company is actually cheaper at 11. 9x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Becton, Dickinson and Company wins at 0. 72x versus Coda Octopus Group, Inc. 's 5. 33x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Coda Octopus Group, Inc.

(CODA) delivered a total return of +55. 9%, compared to -99. 0% for STRATA Skin Sciences, Inc. (SSKN). Over 10 years, the gap is even starker: CODA returned +861. 1% versus SSKN's -99. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), STRATA Skin Sciences, Inc.

(SSKN) is the lower-risk stock at -0. 38β versus Femasys Inc. 's 1. 24β — meaning FEMY is approximately -423% more volatile than SSKN relative to the S&P 500. On balance sheet safety, Coda Octopus Group, Inc. (CODA) carries a lower debt/equity ratio of 1% versus 3% for STRATA Skin Sciences, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Femasys Inc.

(FEMY) is pulling ahead at 40. 8% versus 0. 6% for STRATA Skin Sciences, Inc. (SSKN). On earnings-per-share growth, the picture is similar: Femasys Inc. grew EPS 44. 0% year-over-year, compared to -0. 5% for Becton, Dickinson and Company. Over a 3-year CAGR, FEMY leads at 23. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Coda Octopus Group, Inc.

(CODA) is the more profitable company, earning 15. 5% net margin versus -812. 3% for Femasys Inc. — meaning it keeps 15. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CODA leads at 17. 1% versus -767. 0% for FEMY. At the gross margin level — before operating expenses — CODA leads at 66. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Becton, Dickinson and Company (BDX) is the more undervalued stock at a PEG of 0. 72x versus Coda Octopus Group, Inc. 's 5. 33x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Becton, Dickinson and Company (BDX) trades at 11. 9x forward P/E versus 22. 8x for Coda Octopus Group, Inc. — 10. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for MMSI: 55. 1% to $95. 00.

In this comparison, BDX (2.

8% yield) pays a dividend. FEMY, SSKN, MMSI, CODA do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, STRATA Skin Sciences, Inc.

(SSKN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 38)). Both have compounded well over 10 years (SSKN: -99. 6%, FEMY: -96. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (FEMY (Healthcare) and SSKN (Healthcare) and MMSI (Healthcare) and CODA (Industrials) and BDX (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: FEMY is a small-cap high-growth stock; SSKN is a small-cap quality compounder stock; MMSI is a small-cap quality compounder stock; CODA is a small-cap high-growth stock; BDX is a mid-cap quality compounder stock. BDX pays a dividend while FEMY, SSKN, MMSI, CODA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.